Envista price target lowered to $25 from $33 at Baird

Baird analyst Jeff Johnson lowered the firm’s price target on Envista to $25 from $33 and keeps a Neutral rating on the shares. The firm said 3Q results missed expectations, with management pointing to a notable fall-off in end-market demand trends, especially for higher-acuity ortho/implants, in September/October.